anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present application relates to an O-glycosylated human insulin-like growth factor (IGF-1).  Insulin like growth factor displays insulin-like properties and also has a mediating effect on the action of growth hormone.  Consequently, it is useful in the treatment of both diabetes and pituitary dwarfism.          Unglycosylated IGF-1 must be administered in high doses as it tends to be sequestrated by specific binding proteins circulating in the bloodstream.  High doses can lead to several undesirable side effects such as kidney complaints, obesity and a disturbed water balance.  The present invention provides the preparation of O-glycosylated IGF-1 in yeast cells.  IGF-1 glycosylated on the Thr29 amino acid has been demonstrated to have a reduced affinity to specific binding proteins and a more pronounced effect in lowering blood glucose levels.
BACKGROUND: Lung cancer, a leading cause of cancer mortality, poses significant treatment challenges. The use of immune checkpoint inhibitors (ICIs) has revolutionized therapy, but it is associated with immune-related pneumonitis (IRP). This study systematically reviews and analyzes the impact of Chronic Obstructive Pulmonary Disease (COPD) on the risk of IRP in lung cancer patients undergoing immunotherapy.
METHODS: Adhering to PRISMA guidelines and using the PICO framework, a comprehensive search across PubMed, Embase, Web of Science, and the Cochrane Library was conducted. Inclusion criteria encompassed peer-reviewed studies involving lung cancer patients treated with ICIs, comparing those with and without COPD. The primary outcome was the incidence and risk of IRP. The Newcastle-Ottawa Scale evaluated study quality. The effect size was calculated using random or fixed-effects models based on the observed heterogeneity. We assessed the heterogeneity between studies and conducted a sensitivity analysis.
RESULTS: The search identified 1026 articles, with six meeting the criteria for inclusion. Studies varied in design and geography, predominantly retrospective cohort studies. Patients with COPD had an increased risk of IRP (OR = 1.54, 95% CI [1.24, 1.92, P < 0.01). Subgroup analysis based on radiation therapy exposure (< 40% and ≥ 40%) also indicated a heightened IRP risk in COPD patients. Sensitivity analysis affirmed the robustness of the results, and publication bias was not significant.
CONCLUSIONS: Lung cancer patients with COPD undergoing immunotherapy have a significantly increased risk of developing IRP. This highlights the necessity for vigilant monitoring and individualized treatment strategies to improve the safety and effectiveness of immunotherapy in this group.
INTRODUCTION: Numerous studies have identified diabetes mellites (DM) as a significant risk factor for postoperative wound morbidity, with suboptimal preoperative glycemic control (GC) posing an even greater risk. However, this data largely excludes ventral hernia patients. Our study examined the association between diabetes and preoperative GC and postoperative outcomes following open complex abdominal wall reconstruction (AWR).
METHODS: We identified diabetic patients who had undergone open, elective, clean VHR with transversus abdominis release (TAR) and permanent synthetic mesh at the Cleveland Clinic Foundation between January 2014 and December 2023. Their 30-day outcomes were compared to non-diabetic patients undergoing the same procedure. Subsequently, diabetic patients were categorized based on GC. status: "Optimal GC" (HbA1c < 7%), "Sub-optimal GC" (HbA1c 7-8.4%), and "Poor GC" (HbA1c ≥ 8.5%) and their outcomes were compared.
RESULTS: 514 patients with DM who underwent clean elective TAR were identified, of which 431 met the inclusion criteria. GC was deemed optimal in 255 patients, sub-optimal in 128, and poor in 48 patients. Demographics were similar, except for anticoagulation treatment (p = 0.014). The entire study population exhibited significantly higher rates of wound morbidities and overall complications compared to non-diabetic patients. However, rates of surgical site infection (SSI), surgical site occurrence (SSO), SSO requiring procedural intervention (SSOPI), and reoperation did not differ significantly among the three cohorts of presurgical glycemic control (p = 0.82, p = 0.46, p = 0.51, p = 0.78), respectively. No occurrence of mesh removal was documented.
CONCLUSION: In general, diabetes is a marker for increased wound morbidity and complications following complex abdominal wall reconstruction. However, we could not establish a hard cutoff to justify withholding surgery in symptomatic patients based on an arbitrary HbA1C level. We believe this data is important for shared decision-making when considering AWR for symptomatic ventral hernias in diabetic patients.
Extracellular vesicles (EVs) are a new revelation in cross-kingdom communication, with increasing evidence showing the diverse roles of bacterial EVs (BEVs) in mammalian cells and host-microbe interactions. Bacterial EVs include outer membrane vesicles released by gram-negative bacteria and membrane vesicles generated from gram-positive bacteria. Recently, BEVs have drawn attention for their potential as biomarkers and therapeutic tools because they are nano-sized and can deliver bacterial cargo into host cells. Importantly, exposure to BEVs significantly affects various physiological and pathological responses in mammalian cells. Herein, we provide a comprehensive overview of the various effects of BEVs on host cells (i.e., immune cells, endothelial cells, and epithelial cells) and inflammatory/infectious diseases. First, the biogenesis and purification methods of BEVs are summarized. Next, the mechanisms and pathways identified by BEVs that stimulate either proinflammatory or anti-inflammatory responses are highlighted. In addition, we discuss the mechanisms by which BEVs regulate host-microbe interactions and their effects on the immune system. Finally, this review focuses on the contribution of BEVs to the pathogenesis of sepsis/septic shock and their therapeutic potential for the treatment of sepsis.
This is an open-label (both physician and participant know the name of the study drug), non-randomized, multicenter (when more than one hospital or medical school team work on a medical research study) and long-term efficacy and safety study of JNS013 (combination of tramadol hydrochloride (TRAM) with acetaminophen \[APAP\]) in participants with chronic pain (aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain). This study consists of 4 periods; screening period: 1 week, treatment period I: 4 weeks, treatment period II: 48 weeks and follow-up period: 1 week. During Treatment Period I, restrictions on concomitant treatments will be established and the participants will be treated with one or two tablets of JNS013, four times daily for four weeks. During Treatment Period II, the participants will be treated for 48 weeks using the same dosing method and dose level for JNS013 as was used during Treatment Period I, permitting modifications to the concomitant drugs/therapies as during normal medical care. Throughout both Treatment Period I and Treatment Period II, the decision will be made to permit the participants to select to use either one or two tablets of JNS013 per dose according to the extent of the participant's pain and tolerability. The total duration of treatment period will be of 52 weeks. Efficacy will be assessed using change from baseline in Visual Analogue Scale for pain (VAS24) score at the pre-defined time point until Week 52. Participants safety will be monitored throughout the study.
NEW MATERIAL:A compound of formula I (R is H, benzoyl). EXAMPLE:1-(3-Deoxy-3-fluoro-beta-D-ribofuranosyl)-5-fluorouracil. USE:Antitumor agent. PREPARATION:A furanoside derivative of formula II (R<1> is alkoxy, halogen; R<2>, R<3> are protecting groups; Y is H, eliminating group) is fluorinated to introduce the fluorine atom in the 3-position. When needed, the product is deprotected. Then, residue of 5-fluorouracil group is introduced to give the compound of formula I. The fluorinating agent is suitably a fluorinated tetraalkyl or aralkylammonium and is used in the inert solvent in the form of a solution. The fluorination is conducted at 0 deg.C to room temperature. The compound of formula II has to be synthesized stereospecifically. Further, the hydroxyl groups other than the 3-position should be protected so that they are not fluorinated.
Participants will receive a dose of 40 or 60 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 6 during primary treatment and 40 mg (dose level 1) then 60 mg (dose level 2) during continuous treatment (each cycle consists of 28 days). Participants will also receive an IV dose of rituximab 375 mg/m\^2 on Day 1, and lenalidomide oral dose of 20 mg once daily on Days 1 to 21 during primary treatment for Cycle 1 to 6. Participants will also receive lenalidomide oral dose of 20 mg on Days 1 to 21 at all dose levels during the continuous treatment.
A dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 1, 5 and 10 million cells/kg predicted body weight (PBW). Proceed from lower dose to next higher dose if no safety concerns for each cohort.
A sealing or barrier forming putty caulk of the present invention contains polydimethylsiloxane to provide adhesive and hydrophobic characteristics. The sealing or barrier forming putty caulk also contains propylene glycol in sufficient amounts to provide the composition with hydrophilic properties so the compound will adhere to wet, as well as dry, surfaces or tissue. The sealing or barrier forming composition also contains carboxymethylcellulose to assure that the compound has a homogeneous blend of the ingredients. The sealing or barrier forming composition also contains inert fillers and possibly trace amount of a surfactant. The methods of using the sealing or barrier forming compound of the present invention include delivering the compound efficiently and accurately to the subject region through a syringe. The method of shaping, forming, molding, spreading and rubbing the composition into the desirable configuration in a variety of applications is also set forth to improve the art of dental procedures for the repair of rubber and other dental dams or when procedures require isolating certain tissues, objects or regions as dictated by the dental procedure. The composition and methods of using the present invention include applying and using the composition as a bland bandage to shield and protect irritated, diseased, ulcerated or lesioned tissue.
The control group will not receive an intervention during the first 8-weeks of the study. Being a step-wedge design, this group will receive the same 8-week exercise and education intervention later, after the intervention group has completed the intervention and the post-intervention testing. After the control group has completed the 8-week intervention, they will enter an 8-week maintenance stage. During maintenance, a 30-minute home exercise program is completed twice a week.
1. A method for the treatment of withdrawal symptoms in a human comprising administering to the patient an effective amount of a lipid preparation comprising at least about 10% (w/w) of phosphatidic acid. 2. The method according to claim 1, wherein the treatment is for withdrawal symptoms associated with smoking cessation. 3. A method according to claim 1, wherein the condition or disease is withdrawal symptoms during rehabilitation from drug or alcohol addiction. 4. The method according to claim 1, wherein the treatment is for withdrawal symptoms occuring in menopausal women. 5. A method according to claim 4, for reducing the occurrence of hot flushes during menopause.  6. A method for the treatment of cancer, comprising administering to the patient an effective amount of a lipid preparation comprising at least about 20% (w/w) of phosphatidic acid. 7. A method for the treatment of cancer, comprising administering to the patient an effective amount of a lipid preparation comprising at least about 50% (w/w) of phosphatidic acid. 8. A method according to claim 1, wherein the lipid preparation is obtained by enzymatic treatment of a natural phospholipid preparation with phospholipase-D. 9. A pharmaceutical composition for the treatment of withdrawal symptoms in a human comprising administering to the patient an effective amount of a lipid preparation comprising at least about 10% (w/w) of phosphatidic acid. 10. A pharmaceutical composition according to claim 9, for the treatment of withdrawal symptoms associated with smoking cessation. 11. A pharmaceutical composition acccording to claim 9, for the treatment of withdrawal symptoms during rehabilitation from drug or alcohol addiction. 12. A pharmaceutical composition according to claim 9, for the treatment of withdrawal symptoms in menopausal women. 13. A pharmaceutical composition according to claim 12, for the treatment of menopausal women to reduce occurrence of hot flushes. 14. A pharmaceutical composition comprising, as an active ingredient, a lipid preparation comprising at least about 20% (w/w). 15. A pharmaceutical composition comprising, as an active ingredient, a lipid preparation comprising at least about 50% (w/w). 16. A pharmaceutical composition according to any one of claims 5-15, wherein the lipid preparation was obtained by enzymatic treatment of a natural phospholipid preparation with phospholipase-D.
Coronary CT angiography (CCTA) is an evolving noninvasive modality in diagnosis of coronary artery disease (CAD). Its incremental prognostic value over traditional scheme of risk prediction has repeatedly been demonstrated. Beyond the assessment of CAD severity, the prognostic value of CCTA has increased with comprehensive plaque analysis. Certain plaque features on CCTA have a prognostic value in the prediction of future coronary events. The concept of fractional flow reserve (FFR) has been developed as an invasive index of the functional severity of stenosis. FFR represents maximal blood flow to the myocardium supplied by an artery with stenosis as a fraction of normal maximum flow. In moderate stenotic lesion, determining whether to perform PCI based on FFR is a current guideline, and has been proven to reduce unnecessary revascularization procedure and improve clinical prognosis. However, clinical events still occur in patients with FFR \>0.80. In a recent study, the prognosis in the vessel with FFR \> 0.8 was investigated. However, a comprehensive risk model according to FFR has never been investigated. Therefore, the investigators sought to investigate the prognostic implication of qualitative and quantitative plaque analysis on CCTA according to FFR. The main objective was to develop a comprehensive risk model by using clinical risk factors, FFR, and CCTA parameters.

Patients who underwent CCTA within 90 days before FFR measurement will be included. The study population will be from 2 different registries. The 3V-FFR-FRIENDS registry (NCT0620122050) enrolled a total of 1,136 patients (3,298 vessels). Among them, 299 patients who underwent CCTA within 90 days before FFR measurement will be included. The institutional registry of Tsuchiura Kyodo General Hospital included 448 patients who underwent FFR measurement and CCTA within 90 days. By retrospectively collecting clinical outcome data, coronary angiographic data, physiologic indices, and CCTA data from two registries, the CCTA-FFR Registry for Development of Comprehensive Risk Prediction Model will be created. For 3V FFR-FRIENDS registry (NCT0620122050), the collected clinical data for the previous study will be used, and 5-year outcome data will be collected from Seoul National University Hospital, Keimyung University Dongsan Medical Center, and Inje University Ilsan Paik Hospital. For the Institutional registry of Tsuchiura Kyodo General Hospital registry, the investigators will collect the baseline characteristics of participants, CCTA data, and clinical outcome data followed until Mar 2019.
Pediatric patients with previously-treated, histologically confirmed high-grade glioma with a known H3 K27M mutation, evidence of progressive disease contrast-enhanced brain MRI as defined by RANO-HGG criteria. Prior therapy with at least radiotherapy is required.
A method to increase both the libido and sexual responsiveness in a mammalian female. The method comprises the steps of administering a compound having a combination of DHEA, Yohimbe and L-arginine to that female. When a woman's decreased or absent libido, currently referred to in the medical literature as hypoactive sexual desire, is believed in the gynecologic/urologic communities to be caused by a decreased ‘testosterone effect’, such treatment may be beneficial. This decreased ‘testosterone effect’ can be due to normal aging, contraceptive medications, anti-depressant medication, a lowered cholesterol diet or a decreased percentage of body fat as a result of a rigorous exercise regime. This present invention defines those three above-stated specific nutritional supplements with specific physiological effects well documented in the peer reviewed medical literature. This combination of nutritional supplements increases the testosterone effect in both the brain as well as in the clitoral tissues, to improve a woman's libido, without prescription testosterone preparations, or the uncertainties of non-medically proven herbal remedies.
PURPOSE: We sought to detect left ventricular (LV) adverse alterations in structure and function in type 2 diabetes mellitus (T2DM) patients with or without mild renal dysfunction (MRD) using comprehensive echocardiography techniques and to explore the independent risk factors for LV remodeling (LVR) and dysfunction in these patients.
METHODS: The study included 82 T2DM patients with normal LV ejection fraction (presence (n = 42)/absence (n = 40) of MRD). Age- and gender-matched controls (n = 40) were also recruited. LV structure and function were evaluated using conventional echocardiography and three-dimensional speckle tracking echocardiography (3DSTE). Global longitudinal strain (GLS), global circumferential strain (GCS), global area strain (GAS), and global radial strain (GRS) were all measured using 3DSTE.
RESULTS: Compared with the controls with absolute advantage of LV normal geometry, LVR was more frequently present in the two T2DM groups, with the largest proportion in those with T2DM and MRD (P < 0.001). Fasting plasma glucose (FPG) and MRD were both significant risk factors for LVR in T2DM patients. The detection rates of LV diastolic dysfunction and subclinical systolic dysfunction were significantly higher in the T2DM groups than in the controls (P = 0.000). Moreover, the two case groups also showed significantly lower strain values in multiple directions than the controls (all P < 0.05). FPG was significantly associated with LV diastolic dysfunction, whereas FPG and MRD were both significantly associated with subclinical LV systolic dysfunction in T2DM patients.
CONCLUSIONS: The combined use of conventional echocardiography and 3DSTE allowed the timely detection of early cardiac damage in T2DM patients with or without MRD.
A daily dose of 150 mg to be divided into three doses of 50 mg each. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 200 mg divided into four doses of 50 mg.
PURPOSE: To obtain a dentifrice composition capable of imparting gloss to teeth. CONSTITUTION: This dentifrice composition contains 0.01-10wt.% wax or shellac and 0.01-2wt.% fluorinated oil and/or 0.001-1wt.% germicide as active ingredients and is prepared into a gel-like, a pasty, a powdery, a granular or a liquid dentifrice by suitably blending usually used polishing agents, wetting agents, foaming agents, tacky agents, perfumes, sweetening agents, preservatives, various medicinal ingredients, etc., therewith. When the dentifrice composition is used, essential whiteness, together with gloss, brilliancy and luster, is imparted to teeth. Since innumerable flaws are present on the tooth surfaces, brilliancy is reduced thereby. The tooth surfaces, however, are coated with the wax or shellac and smoothed to suppress the irregular reflection of light. Thereby, the gloss, brilliancy and luster can be imparted to the tooth surfaces. Furthermore, the fluorinated oil can be contained to enhance the gloss and the germicide can be contained to prevent bacteria from propagating in the coated teeth.
Jencycla™ Tablets

Each tablet contains 0.35 mg norethindrone. Inactive ingredients include D&C yellow No. 10, FD&C blue No. 1, lactose anhydrous, magnesium stearate, povidone and sodium starch glycolate.

The chemical name of norethindrone is 17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one. It has a molecular formula of C20H26O2 and a molecular weight of 298.4. It has the following structural formula:

Jencycla meets USP Dissolution Test 2.
This is a single site sham-controlled clinical trial to be conducted at San Diego Sexual Medicine in San Diego, California. Subjects meeting inclusion and exclusion criteria will be randomized to one of two arms, each 2:1 active to sham, treated in 3-week cycles. Arm 1 consists of 5000 shocks the first week and two weeks off for each of three treatment cycles. Arm 2 is made up of 5000 shocks the first week and 3000 active shocks the second and third weeks followed by three weeks without treatment, and then 5000, 3000 and 3000 shocks again over the next three weeks. Each of these is followed by the first follow-up visit at 20 weeks after the first treatment, when GUS and DUS is repeated and validated instruments completed, at which time treatment will be unblinded. SEP diaries will be completed during sexual activity in the screening period and during the 4 weeks prior to the follow up visit. Those subjects assigned to sham will be crossed over to the opposite arm for active treatment (arm 1 sham goes to arm 2 open label and arm 2 sham to arm 1 open label) and begin active treatment with decreased intervals between shocks and therefore decreased number of shocks needed, with 3500 rather than 5000 shocks and 2000 rather than 3000 shocks at a lower frequency at that visit after completing the follow up procedures. Subjects assigned initially to the active arm will have a second follow up 32 weeks after the first treatment, and complete SEP diaries during the 4 weeks preceding this visit. GUS and DUS is performed and validated instruments completed at the last follow up.
PURPOSE:To use polysaccharide N9GI obtained from an extract of bark of Melia azadirachta Linn with hot water as an interferon inducer effective for various kinds of viral infections diseases, having high inducing effect on interferon production and low toxicity. CONSTITUTION:Polysaccharide N9GI is used as an interferon inducer. The polysaccharide N9GI is obtained, from an extract of bark of Melia azadirachta Linn with hot water, and has the following physical and chemical properties. (i) Color and shape: lyophilized interferon inducer is white- light yellowish brown powder. (ii) Solubility: soluble in water, insoluble in methanol, acetone, etc. (iii) Color reaction: positive in phenol-sulfuric acid method, etc. Polysaccharide N9GI is found to have excellent inducing action on interferon production, low toxicity, and to be an improved interferon inducer. It is effective for various kinds of viral infectious diseases, and a dose is usually 100-2,500mg/day.